In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners
Nov 2022
Originally published by In Vivo Pharma Intelligence on November 15, 2022
James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the drug discovery industry.
Summary
-
James West, Director in Lincoln’s Healthcare Group, shares with In Vivo Pharma Intelligence the key trends and M&A dynamics in the drug discovery industry.
- Sign up to receive Lincoln's perspectives
Contributor
Related Perspectives
Lincoln International’s Global Healthcare Group Announces Strong Results in 2022
Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance… Read More
Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence
Originally posted by Scrip on February 10, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry. View the original article.
2022 Global Results
In 2022, Lincoln International continued to design and deliver meaningful solutions and outcomes for clients around the world. Our shared ambition for results achieved through collaboration, thoughtfulness and tailored approaches… Read More
Lincoln International Announces Managing Director Promotions 2022
Lincoln International, a global investment banking advisory firm, is pleased to announce the promotion of six Directors to Managing Director (MD), effective January 1, 2023. “Each of these individuals contributes… Read More
